Prosecution Insights
Last updated: May 29, 2026
Application No. 18/505,192

NAPHTHALENE RING-CONTAINING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF

Non-Final OA §112
Filed
Nov 09, 2023
Priority
May 14, 2021 — CN 202110533784.4 +2 more
Examiner
ROBINSON, MIKHAIL O'DONNEL
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Asieris Pharmaceuticals (Shanghai) Co., Ltd.
OA Round
1 (Non-Final)
57%
Grant Probability
Moderate
1-2
OA Rounds
9m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 57% of resolved cases
57%
Career Allowance Rate
63 granted / 111 resolved
-3.2% vs TC avg
Strong +42% interview lift
Without
With
+41.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
37 currently pending
Career history
156
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
64.3%
+24.3% vs TC avg
§102
11.2%
-28.8% vs TC avg
§112
5.9%
-34.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 111 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Objections Claim 10 is objected to because of the following informalities: Repeats of claim language “the naphthalene ring-containing compound of formula III”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 2-8 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 2, the embodiments of R1-R3 and X1-X6 renders the claim indefinite because it is unclear the limitations of R1-R3 and X1-X6. Although being dependent from claim 1, the R1-R3 and X1-X6 are of formula II and formula I, thus it is not clear if the same limitations of formula III of claim 1 is embodied in formulas I and II. Claims 3-8 are rendered equally as indefinite as depending from claim 2 without further limiting R1-R3 and X1-X6. Allowable Subject Matter Claims 1 and 9-20 are allowed. Closest prior art is of Qian et al. (WO 2018140809 A1), which teaches compound PNG media_image1.png 131 408 media_image1.png Greyscale to treat of estrogen-dependent disease, in particular breast cancer. The teachings of Qian differ from claimed invention of the embodiments of R4 and the core ring being a benzothiophene ring instead of claimed inventions naphthalene ring. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MIKHAIL O'DONNEL ROBINSON whose telephone number is (571)270-0777. The examiner can normally be reached Monday-Friday 7:30am-5:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. MIKHAIL O'DONNEL. ROBINSON Examiner Art Unit 1627 /MIKHAIL O'DONNEL ROBINSON/Examiner, Art Unit 1627 /SARAH PIHONAK/Primary Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Nov 09, 2023
Application Filed
Mar 05, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12629374
ANTIMALARIAL AGENTS
3y 9m to grant Granted May 19, 2026
Patent 12630554
PYRIMIDINONE COMPOUNDS AND USES THEREOF
3y 3m to grant Granted May 19, 2026
Patent 12617781
UTIDELONE SEMI-HYDRATED SINGLE CRYSTAL AND PREPARATION METHOD THEREFOR AND USE THEREOF
3y 10m to grant Granted May 05, 2026
Patent 12612417
Deuterated analogues of selenophenochromenes, synthesis thereof, and methods of using same agents
3y 10m to grant Granted Apr 28, 2026
Patent 12605382
PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, CONTAINING 2,6-DICHLORO-4-(4-(4-HYDROXYCYCLOHEXYLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)PHENOL AS ACTIVE INGREDIENT
2y 5m to grant Granted Apr 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
57%
Grant Probability
98%
With Interview (+41.6%)
3y 4m (~9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 111 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month